NO20043099L - Azaindolylalkylamin-derivater som 5-hydroksytryptamin-6-ligander - Google Patents

Azaindolylalkylamin-derivater som 5-hydroksytryptamin-6-ligander

Info

Publication number
NO20043099L
NO20043099L NO20043099A NO20043099A NO20043099L NO 20043099 L NO20043099 L NO 20043099L NO 20043099 A NO20043099 A NO 20043099A NO 20043099 A NO20043099 A NO 20043099A NO 20043099 L NO20043099 L NO 20043099L
Authority
NO
Norway
Prior art keywords
hydroxytryptamine
ligands
azaindolylalkylamine
derivatives
azaindolylalkylamine derivatives
Prior art date
Application number
NO20043099A
Other languages
English (en)
Norwegian (no)
Inventor
Derek Cecil Cole
Ronald Charles Bernotas
William Joseph Lennox
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20043099L publication Critical patent/NO20043099L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20043099A 2001-12-20 2004-07-19 Azaindolylalkylamin-derivater som 5-hydroksytryptamin-6-ligander NO20043099L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34283801P 2001-12-20 2001-12-20
PCT/US2002/040220 WO2003053970A1 (en) 2001-12-20 2002-12-17 Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands

Publications (1)

Publication Number Publication Date
NO20043099L true NO20043099L (no) 2004-08-17

Family

ID=23343489

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043099A NO20043099L (no) 2001-12-20 2004-07-19 Azaindolylalkylamin-derivater som 5-hydroksytryptamin-6-ligander

Country Status (22)

Country Link
US (3) US6800640B2 (de)
EP (1) EP1456206B1 (de)
JP (1) JP4339123B2 (de)
KR (1) KR20040077861A (de)
CN (1) CN1620455A (de)
AR (1) AR037907A1 (de)
AT (1) ATE396191T1 (de)
AU (1) AU2002360618B2 (de)
BR (1) BR0215151A (de)
CA (1) CA2470832C (de)
CO (1) CO5590960A2 (de)
DE (1) DE60226775D1 (de)
DK (1) DK1456206T3 (de)
ES (1) ES2305338T3 (de)
IL (1) IL162242A0 (de)
MX (1) MXPA04005886A (de)
NO (1) NO20043099L (de)
PL (1) PL370890A1 (de)
RU (1) RU2004122094A (de)
TW (1) TW200301251A (de)
WO (1) WO2003053970A1 (de)
ZA (1) ZA200405733B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2222828B1 (es) 2003-07-30 2006-04-16 Laboratorios Del Dr. Esteve, S.A. Derivados de 1-sulfonilindoles, su preparacion y su aplicacion como medicamentos.
WO2005056547A2 (en) 2003-12-04 2005-06-23 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
ATE412651T1 (de) 2004-06-09 2008-11-15 Glaxo Group Ltd Pyrrolopyridinderivate
KR100958829B1 (ko) * 2004-09-03 2010-05-25 주식회사유한양행 피롤로[2,3-c]피리딘 유도체 및 그의 제조방법
US7541366B2 (en) 2004-09-03 2009-06-02 Yuhan Corporation Pyrrolo[3,2-c]pyridine derivatives and processes for the preparation thereof
KR101142363B1 (ko) 2005-06-27 2012-05-21 주식회사유한양행 피롤로피리딘 유도체를 포함하는 항암제 조성물
EP1947085A1 (de) * 2007-01-19 2008-07-23 Laboratorios del Dr. Esteve S.A. Substituierte Indolsulfonamidverbindungen, ihre Herstellung und ihre Verwendung als Medikamente
AU2008254588B2 (en) * 2007-05-21 2013-01-17 Sgx Pharmaceuticals, Inc. Heterocyclic kinase modulators
CA2687132A1 (en) * 2007-05-24 2008-12-04 Memory Pharmaceuticals Corporation 4' substituted compounds having 5-ht6 receptor affinity
US20100016297A1 (en) * 2008-06-24 2010-01-21 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
US20100022581A1 (en) * 2008-07-02 2010-01-28 Memory Pharmaceuticals Corporation Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity
US20100029629A1 (en) * 2008-07-25 2010-02-04 Memory Pharmaceuticals Corporation Acyclic compounds having 5-ht6 receptor affinity
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
US20100056531A1 (en) * 2008-08-22 2010-03-04 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
US8592448B2 (en) * 2008-11-20 2013-11-26 OSI Pharmaceuticals, LLC Substituted pyrrolo[2,3-b]-pyridines and -pyrazines
US8119683B2 (en) * 2009-08-10 2012-02-21 Taipei Medical University Aryl substituted sulfonamide compounds and their use as anticancer agents
WO2011143646A1 (en) 2010-05-14 2011-11-17 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
WO2012160464A1 (en) * 2011-05-26 2012-11-29 Daiichi Sankyo Company, Limited Heterocyclic compounds as protein kinase inhibitors
EP2734186B1 (de) 2011-07-22 2018-09-12 GlaxoSmithKline LLC Zusammensetzung
CA2880576A1 (en) 2012-08-24 2014-02-27 Glaxosmithkline Llc Pyrazolopyrimidine compounds
CA2890198A1 (en) 2012-11-20 2014-05-30 Diane Mary Coe Novel compounds
RU2643371C2 (ru) 2012-11-20 2018-02-01 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Новые соединения
NZ707319A (en) 2012-11-20 2019-09-27 Glaxosmithkline Llc 5h-pyrrolo[3,2-d]pyrimidin-4-amine compounds and their use in the treatment of allergic diseases and other inflammatory conditions
CN102977094A (zh) * 2012-11-30 2013-03-20 盛世泰科生物医药技术(苏州)有限公司 一种2-羟基-1,5-萘啶的合成方法
EP3083588B1 (de) 2013-12-20 2020-12-09 Sunshine Lake Pharma Co., Ltd. Aromatische heterocyclische verbindungen und deren anwendung in pharmazeutika
JP6515175B2 (ja) 2014-07-08 2019-05-15 サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. 芳香族ヘテロ環誘導体及びその医薬的適用
RU2725886C1 (ru) 2017-03-30 2020-07-07 ЭксДабл-Ю ЛЭБОРЕТРИЗ ИНК. Бициклические гетероарильные производные и их получение и применение
IL311211A (en) 2021-09-03 2024-05-01 Alexander Shulgin Res Institute Inc Asymmetric allyl tryptamines

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977131A (en) 1997-04-09 1999-11-02 Pfizer Inc. Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents
US6100291A (en) * 1998-03-16 2000-08-08 Allelix Biopharmaceuticals Inc. Pyrrolidine-indole compounds having 5-HT6 affinity
GB9820113D0 (en) * 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
CA2370147C (en) * 1999-04-21 2009-07-28 Allelix Biopharmaceuticals Inc. Piperidine-indole compounds having 5-ht6 affinity
AU779832B2 (en) * 1999-08-12 2005-02-10 Nps Pharmaceuticals, Inc. Azaindoles having serotonin receptor affinity
US6476034B2 (en) 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
IL162243A0 (en) * 2001-12-20 2005-11-20 Wyeth Corp Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
JP2008523146A (ja) * 2004-12-14 2008-07-03 ワイス 神経変性障害の処置および予防のための5−ht6アゴニストの使用

Also Published As

Publication number Publication date
CN1620455A (zh) 2005-05-25
JP4339123B2 (ja) 2009-10-07
IL162242A0 (en) 2005-11-20
DK1456206T3 (da) 2008-09-08
CA2470832C (en) 2010-09-21
PL370890A1 (en) 2005-05-30
EP1456206A1 (de) 2004-09-15
US20050020598A1 (en) 2005-01-27
US20030171395A1 (en) 2003-09-11
WO2003053970A1 (en) 2003-07-03
US7585876B2 (en) 2009-09-08
US7297705B2 (en) 2007-11-20
US20080114023A1 (en) 2008-05-15
AU2002360618B2 (en) 2009-01-08
ES2305338T3 (es) 2008-11-01
ATE396191T1 (de) 2008-06-15
BR0215151A (pt) 2004-10-19
MXPA04005886A (es) 2004-09-13
CA2470832A1 (en) 2003-07-03
RU2004122094A (ru) 2005-03-27
US6800640B2 (en) 2004-10-05
AU2002360618A1 (en) 2003-07-09
TW200301251A (en) 2003-07-01
CO5590960A2 (es) 2005-12-30
EP1456206B1 (de) 2008-05-21
AR037907A1 (es) 2004-12-22
DE60226775D1 (de) 2008-07-03
ZA200405733B (en) 2005-10-19
JP2005519046A (ja) 2005-06-30
KR20040077861A (ko) 2004-09-07

Similar Documents

Publication Publication Date Title
NO20043099L (no) Azaindolylalkylamin-derivater som 5-hydroksytryptamin-6-ligander
DK1353904T3 (da) 1-Aryl- eller 1-alkylsulfonylbenzazolderivater som 5-hydroxytryptamin-6-ligander
DK1455779T3 (da) Indolylalkylaminderivater som 5-hydroxytryptamin-6-ligander
NO20031977D0 (no) 1-aryl- eller 1-alkylsulfonyl-heterocyklylbenzazoler som 5- hydroksytryptamin-6-ligander
DK1355904T3 (da) Heterocyclindazol- og -azaindazolforbindelser som 5-hydroxytryptamin-6-ligander
DK1509522T3 (da) 1-(Aminoalkyl)-3-sulfonylazaindoler som 5-hydroxytryptamin-6-ligander
NO20042279L (no) Kinazolinderivater som antitumormidler
NO20042288L (no) Kinazolinderivater som antitumormidler
DK1414803T3 (da) Pyrazolylcarboxanilider som fungicider
DK1397364T3 (da) Hidtil ukendte pyrrolderivater som farmaceutiske midler
ATE319451T1 (de) Tetrahydrochinolin-derivate
NO20035775L (no) 3-fluor-pyrrolidiner som anti-diabetesmidler
NO20034648L (no) Hydroksycyklyloksy-, tioksy- og -aminobenzazol-derivater som 5-hydroksytryptamin-6-ligander
DK1414440T3 (da) N-phenylpyrrolguanidinderivater som melanocortinreceptorligander
ATE312827T1 (de) 3-substituierte-4-pyrimidonderivate
DK1355900T3 (da) Heterocyclylalkylindol- eller -azaindolforbindelser som 5-hydroxytryptamin-6-ligander
DK1322654T3 (da) Platinkomplekser som antitumormidler
NO20034647D0 (no) Hydroksyclylalkoksy-, alkyloksy- og -alkylaminobenzazol- derivater som 5-hydroksytryptamin-6-ligander
DE60223031D1 (de) Arylpiperazin gebundene tetrahydroindolonderivate
DE60202381D1 (de) Paroxetin-n-formyl-derivate
HK1056561A (en) 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
HK1066002A (en) Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
HK1060880A (en) Heterocyclylalkoxy-, -alkylthio- and - alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
HK1060128A (en) Heterocyclyloxy-, -thioxy-and-aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application